Trust leads UK recruitment to breast cancer drug trial | News
Trust leads UK recruitment to breast cancer drug trial
More patients at Royal Surrey have joined a study into a new drug for breast cancer than at any other UK site.
The trial, known as Cambria 2, is looking at whether a new endocrine therapy can reduce the risk of breast cancer returning.
So far, the Cancer Centre team has recruited 22 patients into the randomised trial. They are all at medium or high risk of their cancer coming back after surgery.
Consultant Oncologist Dr Felicity Paterson said: “Some patients have a higher risk of their cancer returning, so we are always looking at ways to improve treatment for them. Researchers believe this new drug may be more effective than the current standard treatment and this clinical trial will help us to find out.”
Surgery is the most common treatment for breast cancer, usually followed by endocrine (hormone) therapy in appropriate patients to reduce the chance of recurrence. In this trial, some patients will receive the new drug, which is called Camizestrant, and others will receive the standard hormone treatment.
Camizestrant works by blocking or slowing cancer growth, preventing oestrogen from entering breast cancer cells. Alongside testing its effectiveness, researchers are also assessing its safety and potential side effects.
Royal Surrey is one of 794 sites worldwide taking part in the study, which is being led by AstraZeneca.